Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment.
TL;DR: MNP-MSN-PLGA-Tf NPs are promising carriers for the delivery of dual drugs for effective treatment of brain glioma and could be enhanced by the presence of magnetic field and the usage of Tf as targeting ligand.
About: This article is published in Biomaterials.The article was published on 2013-11-01. It has received 309 citations till now.
Citations
More filters
TL;DR: An account of ligand-targeted nanoparticles for receptor-mediated cellular internalization as a strategy for modulating the cellular uptake of nanoparticles is presented and prospects, potential, and concrete expectations from the field of targeted nanomedicines and strategies to meet those expectations are provided.
607 citations
Cites background from "Transferrin-conjugated magnetic sil..."
...The targeted nanoparticles resulted in an enhanced anti-glioma activity compared to the non-targeted nanoparticles [111]....
[...]
TL;DR: In this review, the current implications of encapsulation of anticancer agents within polyhydroxyalkanoates, poly-(lactic-co-glycolic acid) and cyclodextrin based nanoparticles to precisely target the tumor site are highlighted and the promising perspectives in this emerging field are discussed.
476 citations
TL;DR: In this review, the barriers to brain-targeted drug delivery are reviewed, including the BBB, blood–brain tumor barrier (BBTB), and nose-to-brain barrier, and delivery strategies are focused on overcoming theBBB, directly targeting diseased cells in the brain, and dual- targeted delivery.
361 citations
TL;DR: An overview of the properties of previously reported PLGA nanoparticles (NPs), their behavior in biological systems, and their use for cancer therapy is given and strategies are emphasized to target PLGA NPs to the tumor site passively and actively.
Abstract: Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid) (PLGA)-based materials are frequently used in such setups. This review article gives an overview of the properties of previously reported PLGA nanoparticles (NPs), their behavior in biological systems, and their use for cancer therapy. Strategies are emphasized to target PLGA NPs to the tumor site passively and actively. Furthermore, combination therapies are introduced that enhance the accumulation of NPs and, thereby, their therapeutic efficacy. In this context, the huge number of reports on PLGA NPs used as drug delivery systems in cancer treatment highlight the potential of PLGA NPs as drug carriers for cancer therapeutics and encourage further translational research.
323 citations
TL;DR: An overview of the different internal and external stimuli most relevant to cancer, and selected examples of stimuli-sensitive combination nanopreparations from the recent literature with respect to each stimulus are discussed.
291 citations
Cites background from "Transferrin-conjugated magnetic sil..."
...reported the development of transferrin (Tf) conjugated magnetic silica poly(D,L-lactic-co-glycolic acid) (PLGA) nanoparticles co-loaded with doxorubicin (DOX) and paclitaxel (PTX) to enable their effective delivery across the blood–brain barrier [153]....
[...]
References
More filters
TL;DR: The latest research on the pathways of entry into live mammalian and plant cells together with intracellular trafficking are described, and the current research progress on the biocompatibility of this material in vitro and in vivo is discussed.
Abstract: The application of nanotechnology in the field of drug delivery has attracted much attention in the latest decades. Recent breakthroughs on the morphology control and surface functionalization of inorganic-based delivery vehicles, such as mesoporous silica nanoparticles (MSNs), have brought new possibilities to this burgeoning area of research. The ability to functionalize the surface of mesoporous-silica-based nanocarriers with stimuli-responsive groups, nanoparticles, polymers, and proteins that work as caps and gatekeepers for controlled release of various cargos is just one of the exciting results reported in the literature that highlights MSNs as a promising platform for various biotechnological and biomedical applications. This review focuses on the most recent progresses in the application of MSNs for intracellular drug delivery. The latest research on the pathways of entry into live mammalian and plant cells together with intracellular trafficking are described. One of the main areas of interest in this field is the development of site-specific drug delivery vehicles; the contribution of MSNs toward this topic is also summarized. In addition, the current research progress on the biocompatibility of this material in vitro and in vivo is discussed. Finally, the latest breakthroughs for intracellular controlled drug release using stimuli-responsive mesoporous-silica-based systems are described.
915 citations
TL;DR: With doxorubicin hydrochloride loaded, Au@SiO(2)-DOX show two light-mediated therapeutic modes: low power density laser-triggered drug release for chemotherapy, and high powerdensity laser-induced hyperthermia, which suggest the potential for in-vivo applications.
Abstract: X. Wu, C. Chen, and co-workers develop mesoporous silica-coated gold nanorods (Au@ SiO2) as a versatile platform for imaging, chemotherapeutics, and hyperthermia. The Au@ SiO2 thus keeps both the unique functions of mesoporous silica nanoparticles and gold nanorods, and also provides a new functionality: lightcontrolled drug release. With integrated functions, such multifunctional theranostic systems are critical to optimize therapeutic efficacy and to improve safety of therapeutic regimes. They will provide more opportunities for on-demand therapy, paving the way to personalized medicine.
869 citations
"Transferrin-conjugated magnetic sil..." refers background in this paper
...Both DOX and PTX are common chemotherapeutic drugs as they have excellent anti-tumor efficacy against various solid tumors [24,25]....
[...]
TL;DR: The broad utility of superparamagnetic iron oxide nanoparticles in molecular imaging is illustrated, including some of the recent developments, such as the transformation of SPIO into an activatable probe termed the magnetic relaxation switch.
Abstract: The field of molecular imaging has recently seen rapid advances in the development of novel contrast agents and the implementation of insightful approaches to monitor biological processes non-invasively. In particular, superparamagnetic iron oxide nanoparticles (SPIO) have demonstrated their utility as an important tool for enhancing magnetic resonance contrast, allowing researchers to monitor not only anatomical changes, but physiological and molecular changes as well. Applications have ranged from detecting inflammatory diseases via the accumulation of non-targeted SPIO in infiltrating macrophages to the specific identification of cell surface markers expressed on tumors. In this article, we attempt to illustrate the broad utility of SPIO in molecular imaging, including some of the recent developments, such as the transformation of SPIO into an activatable probe termed the magnetic relaxation switch.
735 citations
"Transferrin-conjugated magnetic sil..." refers background in this paper
...Besides, iron oxide can be degraded by hydrolytic enzymes in lysosomes [39,40]....
[...]
TL;DR: VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance.
Abstract: Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood vessels of tumors. Unlike antiangiogenic drugs that inhibit the formation of new vessels, VTAs occlude the pre-existing blood vessels of tumors to cause tumor cell death from ischemia and extensive hemorrhagic necrosis. Tumor selectivity is conferred by differences in the pathophysiology of tumor versus normal tissue vessels (e.g., increased proliferation and fragility, and up-regulated proteins). VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance. VTAs are expected to show the greatest therapeutic benefit as part of combined modality regimens. Preclinical studies have shown VTA-induced enhancement of the effects of conventional chemotherapeutic agents, radiation, hyperthermia, radioimmunotherapy, and antiangiogenic agents. There are broadly two types of VTAs, small molecules and ligand-based, which are grouped together, because they both cause acute vascular shutdown in tumors leading to massive necrosis. The small molecules include the microtubulin destabilizing drugs, combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and Oxi 4503, and the flavonoid, DMXAA. Ligand-based VTAs use antibodies, peptides, or growth factors that bind selectively to tumor versus normal vessels to target tumors with agents that occlude blood vessels. The ligand-based VTAs include fusion proteins (e.g., vascular endothelial growth factor linked to the plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs, and gene therapy approaches. Combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and DMXAA are undergoing clinical evaluation. Phase I monotherapy studies have shown that the agents are tolerated with some demonstration of single agent efficacy. Because efficacy is expected when the agents are used with conventional chemotherapeutic drugs or radiation, the results of Phase II combination studies are eagerly awaited.
577 citations
TL;DR: The potential utility of AS1411-functionalized nanoparticles for a therapeutic application in the treatment of gliomas was demonstrated and significantly enhanced cellular association of nanoparticles in C6 glioma cells, and increased the cytotoxicity of its payload.
510 citations
"Transferrin-conjugated magnetic sil..." refers background in this paper
...Poly(D,L-lactic-co-glycolic acid) (PLGA) has been widely used in drug delivery systems due to its biocompatibility and biodegradability [21]....
[...]